Press Release

25 April 2025

Infographic | HitGen FY2024&2025Q1 Report

Infographic | HitGen FY2024&2025Q1 Report
10 April 2025

Mission BioCapital Announces 2024 Platinum Ticket Investments and Opening of $4 Million 2025 Platinum Program Contest

Mission BioCapital (MBC), in partnership with sponsors Eli Lilly and Company (Lilly), Ono Venture Investment (OVI), Alloy Therapeutics, and our newest sponsor, HitGen, announced today that applications are open internationally for the 2025 Platinum Program. MBC's Platinum Program aims to advance high-potential life sciences start-up companies by providing pre-seed funding, global laboratory space, expert mentorship, and discovery services to accelerate their launch and initial development. Early-stage biotechnology innovators from around the globe are invited to apply.
26 December 2024

2025 Pre-Sale|Nucleic Acid Monomer Off 20%|100+ Special Monomers on the Shelf

2025 Pre-Sale Nucleic Acid Monomer Off 20% 100+ Special Monomers on the Shelf
25 October 2024

Infographic | HitGen FY2024 Q3 Report

Infographic | HitGen FY2024 Q3 Report
08 October 2024

Pharma Peers Unite to Build DNA-Encoded Libraries

Finding tools and hits for targets in drug discovery can feel like hunting for four leaf clovers in a blizzard. And researcher Sylvie Sakata was close to giving up on one discovery tool, DNA-encoded libraries, when a new consortium started to fall into place. Now this technology is garnering more interest for its potential to discover new molecular compounds, known as “hits,” to exponentially impact the early research efforts that can lead to potential new medicines.
28 August 2024

Infographic | HitGen FY2024H1 Report

Infographic | HitGen FY2024H1 Report
22 August 2024

Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program

CHENGDU, China, August 22, 2024 – Bridge Biotherapeutics ("Bridge", KQ288330), a clinical-stage biotech company, announced that it has entered into a joint research agreement with HitGen Inc. ("HitGen", SSE: 688222.SH), a Chinese drug discovery platform company. This collaboration builds on successful initial hit finding and identification work from HitGen’s DNA-encoded library (DEL), aiming to further develop the novel hits as promising drug candidates for cancer.
24 April 2024

Infographic | HitGen FY2023&2024Q1 Report

Infographic | HitGen FY2023&2024Q1 Report
08 April 2024

Vernalis announces a drug discovery collaboration with C4X Discovery in inflammatory disease

Vernalis (R&D) Limited (“Vernalis”), a wholly owned subsidiary of HitGen Inc., and C4X Discovery (“C4XD”) are pleased to announce a collaboration to identify modulators of an undisclosed high-value target involved in inflammatory disease.
26 March 2024

HitGen Partners with LabCentral / BioLabs / MBC BioLabs to Accelerate Biotechnology Discovery

[San Francisco, CA – March 25, 2024] – LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership-based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, announced a partnership with HitGen, a global leader in the design, synthesis, and screening of DNA-encoded chemical libraries (DELs).

News

Press Release

Thanks for reading!